Cognition Therapeutics opened lower at $0.67, compared with its previous close of $0.68. In the last trading session, the stock traded between $0.64 and $0.69. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Cognition Therapeutics is now worth
$ 5.60
Resulting in a loss of
$ 94.40 (94.40%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
+$0.00 (+0.25%)
Day High
$0.69
Day Low
$0.64
Day Open
$0.67
Prev Close
$0.68
Volume
3,15,324
1W Return
-0.44%
1M Return
-20.40%
3M Return
-33.10%
6M Return
-42.46%
1Y Return
-61.20%
Market Cap ($ Mn)
65
PE Ratio
-
PB Ratio
2.95
PEG Ratio
-
ROE
-107.89%
ROCE
-106.60%
EPS (TTM)
$-0.04
1 Week
-0.44%
1 Month
-20.40%
3 Months
-33.10%
6 Months
-42.46%
9 Months
-38.27%
Cognition Therapeutics narrows Q3 loss to $4.1M amid rising R&D spend
Net loss narrowed to $4.1 million in Q3 2026 from $4.9 million in Q3 2025. R&D expenses rose 34% YoY to $5.1 million due to Phase 3 trial activities. Grant income surged to $3.0 million, significantly offsetting higher operating costs. Cash position stands at $31.5 million with runway extending into Q4 2027. FDA alignment achieved on primary endpoints for Phase 3 DLB trial.
7 days agoCognition Therapeutics sets FDA meeting for Oct 20 on zervimesine trial
FDA Type C meeting scheduled for October 20, 2026. Focus on aligning endpoints for Phase 3 zervimesine trial. Phase 2 data showed 89% reduction in hallucination/delusion progression. Trial design includes 100 mg daily dose over nine months.
1mo agoCognition Therapeutics CEO to present at H.C. Wainwright conference
CEO Lisa Ricciardi to present at H.C. Wainwright conference on September 15, 2026. Discussion to cover zervimesine development for Alzheimer's and dementia with Lewy bodies. Company plans late-stage trial for DLB psychosis following Phase 2 SHIMMER study signals. Zervimesine currently in Phase 2 START Study for early Alzheimer's disease. Backed by nearly $200 million in NIH and foundation grants.
2mo agoCognition Therapeutics Q2 EPS beats estimate as R&D cuts narrow losses
Cognition Therapeutics beat Q2 EPS estimates with a $(0.04) loss, down from $(0.11) YoY. R&D expenses dropped significantly to $5.1 million, aiding cash preservation. The company secured patent extensions through 2045 and plans Phase 3 initiation in mid-2027.
3mo agoCognition Therapeutics CEO to present Phase 3 plans at B. Riley Summit
Cognition Therapeutics CEO Lisa Ricciardi will present at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026, reviewing the START study and outlining plans for a Phase 3 trial of zervimesine for DLB psychosis.
4mo agoFDA aligns with Cognition on pivotal DLB psychosis trial
Cognition Therapeutics, Inc. announced FDA alignment on a pivotal Phase 3 trial for zervimesine to treat DLB psychosis, confirming the condition as an approvable outcome. The registrational program, targeting patients with hallucinations and delusions, is expected to start in mid-2027. The design follows Phase 2 data showing an 89% slowing in symptom progression.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Cognition Therapeutics is now worth
$ 5.60
Resulting in a loss of
$ 94.40 (94.40%)
Note: Past profits do not guarantee future returns.
